The KEAP1–NRF2 System as a Molecular Target of Cancer Treatment
Open accessThe DOI matches its Crossref record; 114 of the 115 references it cites were found in a registry or an index.
Abstract
The Kelch-like ECH-associated protein 1 (KEAP1)—Nuclear factor erythroid-derived 2-like 2 (encoded by the Nfe2l2 gene; NRF2) system attracts extensive interest from scientists in basic and clinical cancer research fields, as NRF2 exhibits activity as both an oncogene and tumor suppressor, depending on the context. Especially unique and malignant, NRF2-addicted cancers exhibit high levels of NRF2 expression. Somatic mutations identified in the NRF2 or KEAP1 genes of NRF2-addicted cancers cause the stabilization and accumulation of NRF2. NRF2-addicted cancers hijack the intrinsic roles that NRF2 plays in cytoprotection, including antioxidative and anti-electrophilic responses, as well as metabolic reprogramming, and acquire a marked advantage to survive under severe and limited microenvironments. Therefore, NRF2 inhibitors are expected to have therapeutic effects in patients with NRF2-addicted cancers. In contrast, NRF2 activation in host immune cells exerts significant suppression of cancer cell growth, indicating that NRF2 inducers also have the potential to be therapeutics for cancers. Thus, the KEAP1–NRF2 system makes a broad range of contributions to both cancer development and suppression. These observations thus demonstrate that both NRF2 inhibitors and inducers are useful for the treatment of cancers with high NRF2 activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999 · cited 1×
“Of the NRF2 target genes, Nqo1 encodes a representative marker enzyme that has been exploited for the evaluation of NRF2 activity [11].”
BackgroundItoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J. D., & Yamamoto, M. (1999) · Genes & Development · doi:10.1101/gad.13.1.76 · Cited by 3,634 · cited 4×
“As an approach to delineate the domain function, a yeast two-hybrid screen was conducted using the Neh2 domain as bait, and we identified a new molecule, KEAP1 [20].”
BackgroundMethodInfluentialSelf-citationCell Survival Responses to Environmental Stresses Via the Keap1-Nrf2-ARE Pathway
Kensler, T. W., Wakabayashi, N., & Biswal, S. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141046 · Cited by 3,630 · cited 1×
“our body is equipped with the ability to eliminate these toxic xenobiotics and adapt to the environment, which we refer to as the adaptive response or the environmental stress response [3,4].”
BackgroundNegative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551 · cited 6×
“In contrast, Pten (phosphatase and tensin homolog deleted on chromosome 10) dephosphorylates PIP3 to PIP2 and thus counteracts the action of PI3K [26]. v-akt murine thymoma viral oncogene homolog (protein kinase B; Akt) is activated via phosphorylation.”
BackgroundInfluentialTracking the Evolution of Non–Small-Cell Lung Cancer
Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., Shafi, S., Johnson, D. H., Mitter, R., Rosenthal, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616288 · Cited by 2,349 · cited 1×
“Aberrant activation of NRF2 has been shown to provoke malignant growth and anticancer drug resistance in many types of cancers [53] (see Section 6).”
BackgroundKomatsu, M., Kurokawa, H., Waguri, S., Taguchi, K., Kobayashi, A., Ichimura, Y., Sou, Y.-S., Ueno, I., Sakamoto, A., Tong, K. I., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2021 · Cited by 2,288 · cited 1×
“As p62 is a scaffold or chaperone protein in autophagy [36], the most plausible scenario is that p62 binds to KEAP1 and brings KEAP1 to the autophagosome.”
BackgroundSelf-citationOncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277 · cited 1×
“Furthermore, NRF2 gene expression is transcriptionally regulated by oncogenes, such as K-Ras and c-Myc [75].”
BackgroundKobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224 · cited 2×
“NRF2 has a very short half-life, which is less than 20 min [9,10].”
BackgroundThe KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis
Yamamoto, M., Kensler, T. W., & Motohashi, H. (2018) · Physiological Reviews · doi:10.1152/physrev.00023.2017 · Cited by 1,968 · cited 1×
“Nuclear factor erythroid-derived 2-like 2; encoded by the Nfe2l2 gene (NRF2) is a transcription factor that controls the environmental stress response by changing gene expression profiles [5].”
BackgroundSelf-citationAnalysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898 · cited 1×
“To verify this notion, we exploited the KrasG12Ddriven lung adenocarcinoma system [96] and examined two mouse models with different NRF2 activity levels in the presence of adenovirus expressing Cre recombinase [97]: KEAP1flox-A mice [17] and KEAP1flox-B mice [98].”
Method
Cited by
Defining roles of specific reactive oxygen species (ROS) in cell biology and physiology
Sies, H., Belousov, V. V., Chandel, N. S., Davies, M. J., Jones, D. P., Mann, G. E., Murphy, M. P., Yamamoto, M., & Winterbourn, C. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00456-z · Cited by 1,735
Self-citationNrf2 and Oxidative Stress: A General Overview of Mechanisms and Implications in Human Disease
Ngo, V., & Duennwald, M. L. (2022) · Antioxidants · doi:10.3390/antiox11122345 · Cited by 1,130
Oxidative cell death in cancer: mechanisms and therapeutic opportunities
An, X., Yu, W., Liu, J., Tang, D., Yang, L., & Chen, X. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-06939-5 · Cited by 523
“The role of NRF2 has been con fi rmed beyond initial assumptions, presenting both challenges and opportunities in cancer treatment [69].”
BackgroundMultifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 521
“68 Tumorigenicity is regulated by two means of the Nrf2 antioxidant reply, either via Keap1-dependent and Keap1-independent mechanisms or via stimulating the development and cancer-cell survival, which are already inducted since Nrf2 and the anti-oxidative reply aids tumors in dealing with…”
BackgroundWang, Y., Cheng, H., Wang, T., Zhang, K., Zhang, Y., & Kang, X. (2023) · Cell Proliferation · doi:10.1111/cpr.13448 · Cited by 225
“release of Nrf2, which leads to the accumulation of Nrf2 in the cytoplasm and subsequent nuclear transfer.(104) After entering the nucleus,”
Background
Metadata
- Authors
- Taguchi, K., & Yamamoto, M.
- Affiliations
- Tohoku University (JP)
- Corresponding author
- Yamamoto, Masayuki
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2020-12-26
- Volume
- 13
- Issue
- 1
- Pages
- 46
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC7795874
- OpenAlex
- W3114836680
- Cited by
- 195
- References
- 115
- Citations by year
- 2026: 21 · 2025: 34 · 2024: 38 · 2023: 34 · 2022: 46 · 2021: 21
- FWCI
- 2.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology (19H05649, 19K07395)
- Core Research for Evolutional Science and Technology (16gm0410013h0006)
- Japan Agency for Medical Research and Development (JP20cm0106101)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Keywords
- Keap1, Nrf2, Nrf2 inhibitors, Nrf2 inducers, oncogene addiction, tumor suppressor, oxidative stress response, metabolic reprogramming, tumor microenvironment, host immune cells, cancer therapy targets
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The KEAP1–NRF2 System as a Molecular Target of Cancer Treatment. https://app.cochat.ai/papers/10.3390/cancers13010046
- The paper
- Taguchi, K., & Yamamoto, M. (2020). The KEAP1–NRF2 System as a Molecular Target of Cancer Treatment. Cancers. https://doi.org/10.3390/cancers13010046
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.